Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
Pfister DG, Haddad RI, Worden FP, Weiss J, Mehra R, Chow LQM, Liu SV, Kang H, Saba NF, Wirth LJ, Sukari A, Massarelli E, Ayers M, Albright A, Webber AL, Mogg R, Lunceford J, Huang L, Cristescu R, Cheng J, Seiwert TY, Bauml JM. Pfister DG, et al. Among authors: seiwert ty. Cancer Med. 2023 Mar;12(6):6603-6614. doi: 10.1002/cam4.5434. Epub 2022 Dec 7. Cancer Med. 2023. PMID: 36479637 Free PMC article.
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Seiwert TY, Wildsmith S, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, Weiss J, Machiels JP, Baxi S, Baker V, Evans B, Morsli N, Jill Walker, Real K, L'Hernault A, Psyrri A. Seiwert TY, et al. Cancer Immunol Immunother. 2024 Mar 2;73(4):70. doi: 10.1007/s00262-024-03643-3. Cancer Immunol Immunother. 2024. PMID: 38430375 Free PMC article.
Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
Rais R, Lemberg KM, Tenora L, Arwood ML, Pal A, Alt J, Wu Y, Lam J, Aguilar JMH, Zhao L, Peters DE, Tallon C, Pandey R, Thomas AG, Dash RP, Seiwert T, Majer P, Leone RD, Powell JD, Slusher BS. Rais R, et al. Sci Adv. 2022 Nov 18;8(46):eabq5925. doi: 10.1126/sciadv.abq5925. Epub 2022 Nov 16. Sci Adv. 2022. PMID: 36383674 Free PMC article.
Chemoradiotherapy for locally advanced head and neck cancer.
Salama JK, Seiwert TY, Vokes EE. Salama JK, et al. Among authors: seiwert ty. J Clin Oncol. 2007 Sep 10;25(26):4118-26. doi: 10.1200/JCO.2007.12.2697. J Clin Oncol. 2007. PMID: 17827462 Review. No abstract available.
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, Beniwal P, Blair EA, Stenson KM, Portugal L, Seiwert T, Williams RD, Dekker AJ, Witt ME, Vokes EE, Cohen EEW. Villaflor VM, et al. Ann Oncol. 2011 Nov;22(11):2501-2507. doi: 10.1093/annonc/mdq785. Epub 2011 Mar 8. Ann Oncol. 2011. PMID: 21385883 Free article. Clinical Trial.
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE. Seiwert TY, et al. Ann Oncol. 2013 Mar;24(3):769-76. doi: 10.1093/annonc/mds523. Epub 2012 Oct 26. Ann Oncol. 2013. PMID: 23104721 Free PMC article. Clinical Trial.
EGFR-directed treatments in SCCHN.
Vokes EE, Seiwert TY. Vokes EE, et al. Among authors: seiwert ty. Lancet Oncol. 2013 Jul;14(8):672-3. doi: 10.1016/S1470-2045(13)70215-8. Epub 2013 Jun 6. Lancet Oncol. 2013. PMID: 23746667 No abstract available.
143 results